| Budget Amount *help |
¥69,420,000 (Direct Cost: ¥53,400,000、Indirect Cost: ¥16,020,000)
Fiscal Year 2019: ¥13,520,000 (Direct Cost: ¥10,400,000、Indirect Cost: ¥3,120,000)
Fiscal Year 2018: ¥13,520,000 (Direct Cost: ¥10,400,000、Indirect Cost: ¥3,120,000)
Fiscal Year 2017: ¥13,520,000 (Direct Cost: ¥10,400,000、Indirect Cost: ¥3,120,000)
Fiscal Year 2016: ¥13,520,000 (Direct Cost: ¥10,400,000、Indirect Cost: ¥3,120,000)
Fiscal Year 2015: ¥15,340,000 (Direct Cost: ¥11,800,000、Indirect Cost: ¥3,540,000)
|
|---|
| Outline of Final Research Achievements |
The first enantioselective total synthesis of anti-cancer drug candidate cotylenin A has been achieved. In the process of its synthesis, a new acyl radical cyclization and stereoselective reducing reagent have been developed. A compound expected to be converted to bruceanthin was synthesized via Au(I)-catalyzed ene-yne cycloisomerization. A novel chiral NHC ligand effective for ene-yne cycloisomerization has been developed. An immobilized asymmetric copper catalyst effective for catalytic asymmetric cyclopropanation has been developed. A derivative with higher biological activity than Scabronin G has been designed and synthesized. A Liebeskind-Srogl coupling/intramolecular Diels-Alder reaction cascade has been developed. The α-imidation of α,β-unsaturated cyclic amide was formed in 2% yield by the batch method, but the yield was significantly improved to 78% by the flow method.
|
